Phase III double-blind randomised placebo controlled trial of atezolizumab in combination with paclitaxel and carboplatin in women with advanced/recurrent endometrial cancer.

See ANZCTR for full trial details >

 

Trial Summary:

The purpose of this study is to measure the effect of atezolizumab given in combination with paclitaxel and carboplatin and placebo given in combination with paclitaxel and carboplatin. This study will also investigate the activity of this treatment on the control of cancer growth.

Supported By:

ANZGOG, MaNGO (Mario Negri Gynecologic Oncology group)

Eligibility:

Women aged 18 years or above, with newly diagnosed advanced endometrial cancer or recurrent endometrial cancer if not yet treated for recurrent disease.

Registration ID:

ACTRN12619000900112

Participation:

International

Australian Lead Group:

ANZGOG

Status:

Recruiting

Activation Date:

 August 2020

Chairs:

Professor Yoland Antill

Contact:

attend.study@sydney.edu.au